Click image to enlarge
The U‑PLEX platform makes it easy to create multiplex immunoassays. Using two simple tools - a 10-spot U‑PLEX plate and unique Linkers - you can build multiplex panels for any combination of analytes. The analytes in the U‑PLEX menu are organized into U‑PLEX Groups. Assays within the same U‑PLEX Group have been tested for multiplex compatibility and can be combined in panels with confidence.
The U‑PLEX Custom Metabolic Group 1 (mouse) products (Table 1) enable multiplex panels that combine U‑PLEX metabolic assays with other content. They are fulfilled with a U‑PLEX plate where some of the spots measure U‑PLEX analytes and some of the spots are left “open”. The “open” spots can be used for custom content such as MSD’s R-PLEX Antibody Sets or antibodies from other sources. Ordering a Custom U‑PLEX assay is simple and can be done online with our
U‑PLEX Assay Designer.
Analyte |
LLOD - ULOD |
units |
BAFF |
0.51 - 4,000 |
pg/mL |
BCA-1/BLC |
21 - 32,000 |
pg/mL |
BDNF |
0.72 - 2,000 |
pg/mL |
CD40/TNFRSF5 |
2.6 - 8,000 |
pg/mL |
C-Peptide |
220 - 125,000 |
pg/mL |
Eotaxin |
4.6 - 15,000 |
pg/mL |
EPO |
4.5 - 12,500 |
pg/mL |
FGF-21 |
2.8 - 8,230 |
pg/mL |
Ghrelin (active) |
13 - 7,160 |
pg/mL |
Ghrelin (total) |
1.7 - 2,710 |
pg/mL |
GLP-1 (active) |
0.14 - 57 |
pM |
GLP-1 (inactive) |
1.5 - 576 |
pM |
GLP-1 (total) |
0.59 - 576 |
pM |
Glucagon |
0.13 - 156 |
pM |
GM-CSF |
0.16 - 1,000 |
pg/mL |
IFN-α |
140 - 100,000 |
pg/mL |
IFN-β |
5.2 - 6,000 |
pg/mL |
IFN-γ |
0.16 - 2,900 |
pg/mL |
IL-1β |
3.1 - 13,000 |
pg/mL |
IL-2 |
1.1 - 10,900 |
pg/mL |
IL-4 |
0.56 - 10,000 |
pg/mL |
IL-5 |
0.63 - 2,800 |
pg/mL |
IL-6 |
4.8 - 16,000 |
pg/mL |
IL-9 |
1.4 - 8,900 |
pg/mL |
IL-10 |
3.8 - 22,800 |
pg/mL |
IL-12/IL-23p40 |
1.4 - 20,400 |
pg/mL |
IL-12p70 |
48 - 89,000 |
pg/mL |
IL-13 |
2.7 - 22,800 |
pg/mL |
IL-15 |
24 - 131,000 |
pg/mL |
Analyte |
LLOD - ULOD |
units |
IL-16 |
3.6 - 6,250 |
pg/mL |
IL-17A |
0.30 - 2,150 |
pg/mL |
IL-17A/F |
0.61 - 10,600 |
pg/mL |
IL-17C |
2.3 - 45,600 |
pg/mL |
IL-17E/IL-25 |
1.6 - 18,900 |
pg/mL |
IL-17F |
24 - 52,600 |
pg/mL |
IL-21 |
6.5 - 40,600 |
pg/mL |
IL-22 |
1.2 - 1,850 |
pg/mL |
IL-23 |
4.9 - 20,400 |
pg/mL |
IL-27p28/IL-30 |
8.7 - 73,200 |
pg/mL |
IL-31 |
45 - 66,200 |
pg/mL |
IL-33 |
2.2 - 36,000 |
pg/mL |
Insulin |
3.0 - 5,500 |
μIU/mL |
IP-10 |
0.51 - 4,900 |
pg/mL |
KC/GRO |
4.8 - 16,000 |
pg/mL |
Leptin |
11 - 50,000 |
pg/mL |
MCP-1 |
1.4 - 1,400 |
pg/mL |
MCP-5/CCL12 |
0.14 - 1,500 |
pg/mL |
MDC |
13 - 10,000 |
pg/mL |
MIP-1α |
0.21 - 2,100 |
pg/mL |
MIP-1β |
13 - 30,800 |
pg/mL |
MIP-2 |
0.30 - 2,000 |
pg/mL |
MIP-3α |
0.10 - 2,500 |
pg/mL |
MMP-9 (total) |
49 - 80,000 |
pg/mL |
PYY (total) |
1.1 - 4,000 |
pg/mL |
RANTES |
0.72 - 2,000 |
pg/mL |
TARC |
0.32 - 1,200 |
pg/mL |
TNF-α |
1.3 - 6,200 |
pg/mL |
VEGF-A |
0.77 - 12,100 |
pg/mL |
-
-
Specifications
-
-
-
Documentation
-
References
Application(s)
|
|
Metabolic
|
|
Species
|
|
Mouse
|
|
Instrument(s)
|
|
SECTOR Imager 2400
,
SECTOR Imager 6000
,
MESO QuickPlex SQ 120
,
MESO QuickPlex SQ 120MM
,
MESO SECTOR S 600
,
MESO SECTOR S 600MM
|
|
U-PLEX Group Compatibility
|
|
Metabolic Group 1
|
|
Plate Type
|
|
96-well
|
|
Sample Type
|
|
Cell Culture Media, EDTA Plasma, P800 Plasma, Serum
|
|
Usage Statement
|
|
For Research Use Only. Not for use in diagnostic procedures.
|
|
Storage Condition
|
|
Multi-Component
|
|
Schedule B Code
|
|
3822.19.0000
|
|
Product Inserts
|
|
|
Datasheets
|
|
View More
|
Product Highlights
|
|
|
Title
|
Journal
|
Year
|
|
Islet Autoantibody Standardization Program: interlaboratory comparison of insulin autoantibody assay performance in 2018 and 2020 workshops
|
|
|
|
Twenty-eight day repeated exposure of human 3D bronchial epithelial model to heated tobacco aerosols indicates decreased toxicological responses compared to cigarette smoke
|
|
|
|
A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma
|
|
|
|
Viral Antigen and Inflammatory Biomarkers in Cerebrospinal Fluid in Patients With COVID-19 Infection and Neurologic Symptoms Compared With Control Participants Without Infection or Neurologic Symptoms
|
|
|
|
Characterization and Biomarker Analyses of Post-COVID-19 Complications and Neurological Manifestations
|
|
|
|
View All
|
Customer Service/Orders
Scientific/Technical Support
Instrument Support
Company Headquarters